Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

BTIG analyst Gray Powell raised the firm’s price target on Zscaler (ZS) to $238 from $205 and keeps a Buy rating on the shares. The firm’s ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Investors should start looking at restaurant names that have timely setups, said Jonathan Krinsky, chief market technician at ...

Oil (CL1:COM) prices and the broader energy sector have been among the worst-performing areas of the economy since the start ...

BTIG analyst Andrew Harte is praising MicroStrategy's (NASDAQ:MSTR) plan announced at the end of October to raise $42B of ...

On Tuesday, Vuzix Corp (VUZI) stock saw a decline, ending the day at $1.97 which represents a decrease of $-0.28 or -12.44% from the prior close of $2.25. The stock opened at $2.38 and touched a low ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable ...

Analysts expect Frontline to report quarterly earnings at 38 cents per share. That's up from 36 cents per share a year ago.

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...